Valeant CEO talks about Afexa bid
4:06 PM, E.T. | August 30, 2011Canadian
Valeant Pharmaceuticals is looking to add another company to its lengthy list of acquisitions after it announced on Tuesday a friendly $76-million bid for Afexa Life Sciences. Chairman and CEO Mike Pearson talks to BNN about Valeant's offer.